Pazopanib exposure decreases as a result of an ifosfamide-dependent drug–drug interaction: results of a phase I study

Open-label feasibility study of pazopanib, carboplatin and paclitaxel in women with newly diagnosed, untreated, gynaecologic tumours: a phase I/II trial of the AGO study group

(2012) A du Bois et al.   BRITISH JOURNAL OF CANCER

Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study

(2012) S Sleijfer et al.   BRITISH JOURNAL OF CANCER

A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors

(2012) Ruth Plummer et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A new approach for rapid and reliable enumeration of circulating endothelial cells in patients

(2012) J. KRAAN et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

(2012) Winette TA van der Graaf et al.   LANCET

Phase I Study of Pazopanib in Combination with Paclitaxel and Carboplatin Given Every 21 Days in Patients with Advanced Solid Tumors

(2012) H. A. Burris et al.   MOLECULAR CANCER THERAPEUTICS

Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies

(2010) P Hamberg et al.   BRITISH JOURNAL OF CANCER

An Evaluation of the Drug Interaction Potential of Pazopanib, an Oral Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, Using a Modified Cooperstown 5+1 Cocktail in Patients With Advanced Solid Tumors

(2010) B C Goh et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Dose-escalation models for combination phase I trials in oncology

(2010) Paul Hamberg et al.   EUROPEAN JOURNAL OF CANCER

Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial

(2010) Cora N. Sternberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Study of Pazopanib in Combination with Weekly Paclitaxel in Patients with Advanced Solid Tumors

(2010) A. R. Tan et al.   ONCOLOGIST

(Pre-)Clinical Pharmacology and Activity of Pazopanib, a Novel Multikinase Angiogenesis Inhibitor

(2010) P. Hamberg et al.   ONCOLOGIST

Phase I Trial of Pazopanib in Patients with Advanced Cancer

(2009) H. I. Hurwitz et al.   CLINICAL CANCER RESEARCH

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER